What we know about long-acting injectable antipsychotics can help innovate HIV care

Research output: Contribution to journalArticlepeer-review

Abstract

Long-acting injectable antiretroviral therapy (LA-ART) is a powerful new addition to the treatments available for patients living with HIV, but broad acceptance and uptake could be compromised by what we know about patients' and clinicians' experiences with long-acting injectable antipsychotics (LAI-APs). Treatment of stigmatized conditions, such as psychiatric illness or HIV, using long-acting injection is ethically fraught with patients' fear of coercion and forced administration. Strategies that emphasize patient-centered, patient-directed care and that place limits on when LAI can be administered forcibly can help promote LA-ART's acceptance and use.

Original languageEnglish (US)
Pages (from-to)405-409
Number of pages5
JournalAMA Journal of Ethics
Volume23
Issue number5
DOIs
StatePublished - May 2021
Externally publishedYes

ASJC Scopus subject areas

  • Issues, ethics and legal aspects
  • Health(social science)
  • Health Policy

Fingerprint

Dive into the research topics of 'What we know about long-acting injectable antipsychotics can help innovate HIV care'. Together they form a unique fingerprint.

Cite this